Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Funding Agency:
National Institutes of Health

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:

  • Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.

NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

UG3/UH3

PAR-17-465: Bench Testing Therapeutic/Indication Paring Strategies (UG3/UH3)

Applicable Receipt Date:

  • June 26, 2020

U34

PA-18-462:Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

Applicable Receipt Date:

  • June 16, 2020
  • October 16, 2020

U01

PAR-18-332: Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

Applicable Receipt Dates:

  • June 5, 2020
  • October 5, 2020

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 16, 2020